Please upgrade your browser.
The response of a patient with metastatic brain tumors to treatment with stereotactic radiosurgery in the first six-to-twelve weeks can indicate whether follow-up treatments and monitoring are necessary, according to research conducted at the University of North Carolina.
The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression.
Complication rates of open partial nephrectomies (OPN) and minimally invasive partial nephrectomies (MIPN) have largely been reported by single and multi-institutional tertiary care centers.
One in three patients with kidney cancer eligible to receive one of two new medicines – sunitinib or pazopanib – did not get them due to the area they live in.
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
DNA aptamers represent a novel strategy in anti-cancer medicine.
5-8% of kidney cancers have a genetic predisposition.
VIDEO: NCI's Dr. Marston Linehan on 30 years of research into the genetic basis of kidney cancer.
The incidence of renal cell carcinoma (RCC) has increased steadily in past few decades and is partially attributable to the increased utilization of cross-sectional imaging.
This is a failure by President Obama's own standard. About one of six Americans under age 65 lack insurance in the official statistics. So where are they? Either Democrats exaggerated the problem to pass the new entitlement. Or else individuals don't think ObamaCare plans offer value, and they're choosing to stay uninsured or buy insurance off the exchanges where the regulations are slightly looser.
|Powered by NeonCRM|